Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Portuguese Journal of Nephrology & Hypertension
versión impresa ISSN 0872-0169
Resumen
BORGES, Madalena Almeida et al. Primary Hyperoxaluria Type 1: The First Patient Treated with Lumasiran in Portugal. Port J Nephrol Hypert [online]. 2023, vol.37, n.2, pp.93-96. Epub 30-Jun-2023. ISSN 0872-0169. https://doi.org/10.32932/pjnh.2023.03.233.
Primary hyperoxaluria type 1 is a rare genetic disease caused by mutations in AGXT, leading to an excessive hepatic production of oxalate, resulting in urolithiasis, nephrocalcinosis and chronic kidney disease. The authors present the case of a young female with PH1 who is the first patient treated with lumasiran in Portugal, and currently has a follow-up of 18 months.
Palabras clave : Hyperoxaluria, Primary/drug therapy; Kidney Calculi; RNA, Small Interfering/therapeutic use; RNAi Therapeutics.